WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Ownership - Who owns Inhibikase Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Inhibikase Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Roberto BelliniDirector2024-10-211,460,000$1.37
$2.00MBuy
Arvind KushDirector2024-10-21145,000$1.37
$198.65kBuy
Amit MunshiDirector2024-10-21365,000$1.37
$500.05kBuy

1 of 1

IKT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when IKT insiders and whales buy or sell their stock.

IKT Shareholders

What type of owners hold Inhibikase Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sands Capital Life Sciences Pulse Fund II LP14.69%10,950,000$17.08MInsider
Sands Capital Alternatives LLC14.69%10,950,000$17.08MInstitution
Soleus Capital Management LP8.49%6,325,000$9.87MInstitution
Fairmount Funds Management LLC8.22%6,125,000$9.56MInstitution
Perceptive Advisors LLC7.29%5,432,293$8.47MInstitution
Commodore Capital LP7.24%5,397,488$8.42MInstitution
Milton H. Werner7.19%5,359,022$8.36MInsider
Adar1 Capital Management LLC6.87%5,122,105$7.99MInstitution
Vanguard Group Inc4.33%3,224,370$5.03MInstitution
Blackrock Inc3.66%2,728,168$4.26MInstitution

1 of 3

IKT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IKT72.94%27.06%Net Buying
SEER47.01%52.99%Net SellingNet Selling
BMEA48.27%28.91%Net Buying
INO19.13%58.44%Net Selling
ONCY1.73%0.00%
View Top Biotech Stocks

Inhibikase Therapeutics Stock Ownership FAQ

Who owns Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ: IKT) is owned by 73.15% institutional shareholders, 27.13% Inhibikase Therapeutics insiders, and 0.00% retail investors. Sands Capital Life Sciences Pulse Fund II LP is the largest individual Inhibikase Therapeutics shareholder, owning 10.95M shares representing 14.69% of the company. Sands Capital Life Sciences Pulse Fund II LP's Inhibikase Therapeutics shares are currently valued at $17.08M.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.